Cargando…

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS

Detalles Bibliográficos
Autores principales:	Bose, Prithviraj, Mohan, Sanjay, Oh, Stephen, Gotlib, Jason, Ritchie, Ellen, Shimomura, Taizo, Ali, Haris, Boyer, Francoise, Guglielmelli, Paola, Hunter, Anthony M., Lamothe, Betty, Cui, Yi, Seguy, Francis, Mcbride, Amanda, Palandri, Francesca, Takeuchi, Masahiro, Kiladjian, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431260/ http://dx.doi.org/10.1097/01.HS9.0000970988.41693.dd

Ejemplares similares

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
por: Watts, Justin M., et al.
Publicado: (2023)

M10.2.2: Definition of cryomodule interface
por: Parma, V, et al.
Publicado: (2011)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Suppression and Regression of Choroidal Neovascularization in Mice by a Novel CCR2 Antagonist, INCB3344
por: Xie, Ping, et al.
Publicado: (2011)

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
por: Griesshammer, Martin, et al.
Publicado: (2018)

Cumulative incidence and risk factors for limber tail in the Dogslife labrador retriever cohort
por: Pugh, C. A., et al.
Publicado: (2016)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Carbon Costs of Constitutive and Expressed Resistance to a Non-Native Pathogen in Limber Pine
por: Vogan, Patrick J., et al.
Publicado: (2016)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study
por: Palandri, Francesca, et al.
Publicado: (2023)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
por: Harrison, C., et al.
Publicado: (2022)

Limber Pine (Pinus flexilis James), a Flexible Generalist of Forest Communities in the Intermountain West
por: Windmuller-Campione, Marcella A., et al.
Publicado: (2016)

Fine dissection of limber pine resistance to Cronartium ribicola using targeted sequencing of the NLR family
por: Liu, Jun-Jun, et al.
Publicado: (2021)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

1022. The Role of Baseline Body Temperature in Neutropenic Fever
por: Corsi, Anthony J, et al.
Publicado: (2022)

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
por: Elli, Elena Maria, et al.
Publicado: (2019)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
por: Verstovsek, Srdan, et al.
Publicado: (2017)

1022. Impact of Hospitalization on Antiretroviral Therapy for People Living with HIV
por: Ladak, Amber, et al.
Publicado: (2020)

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide
por: Castellana, Giuseppe, et al.
Publicado: (2015)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Forecasting Distributional Responses of Limber Pine to Climate Change at Management-Relevant Scales in Rocky Mountain National Park
por: Monahan, William B., et al.
Publicado: (2013)

Living with metastatic breast cancer (LIMBER): experiences, quality of life, gaps in information, care and support of patients in the UK
por: Fallowfield, L., et al.
Publicado: (2023)

INCB, WHO AND UNODC STATEMENT ON ACCESS TO INTERNATIONALLY CONTROLLED MEDICINES DURING COVID-19 PANDEMIC
Publicado: (2020)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis
por: Buks, Ralfs, et al.
Publicado: (2021)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
por: Breccia, Massimo, et al.
Publicado: (2019)

Effect of limbering up of the muscles attached to the pelvis on the strength of upper and lower extremity and trunk muscles through the transitional network
por: Azuma, Yuichi, et al.
Publicado: (2018)

Molecular and clinical characterization of PTRF in glioma via 1,022 samples
por: Sun, Si, et al.
Publicado: (2023)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2010)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Association Mapping and Development of Marker-Assisted Selection Tools for the Resistance to White Pine Blister Rust in the Alberta Limber Pine Populations
por: Liu, Jun-Jun, et al.
Publicado: (2020)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7k3jv9j9cke6gbgch64b5pggjq